Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in ...
Drug Store News10d
Samsung Bioepis, Teva ink deal for Soliris biosimilar
Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...
Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...
Nasdaq15d
Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
(RTTNews) - Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis biosimilar to ...
Nasdaq15d
Samsung Bioepis and Teva Pharmaceutical Enter Partnership for EPYSQLI® Biosimilar to Enhance Treatment Options for Rare Disease Patients in the U.S.
EPYSQLI's approval by the FDA represents a milestone for Teva, potentially increasing revenue and market share in the fast-growing biosimilars market. Teva's commercial responsibilities for ...
WGNO15d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS ...